Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
CDXS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Codexis, Inc.NASDAQ: CDXS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$6.45M, compared with -$17.83M a year earlier. Trailing-twelve-month EBITDA was -$22.06M.
Context
- EBITDA amounted to 48.1% of revenue in FY2025, down 41.9 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$25.82M (+23.8%) for the fiscal year ending Dec 2026, a slowdown from the +36.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$6.45M-154.4% QoQ
- Last fiscal yearDec 2025
- -$33.87M+36.6% YoY
- LTMMar 2026
- -$22.06M+62.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +63.8% | -7.5% | -71.3 pp |
| 1 year | +36.6% | +23.8% | -12.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (33.87M) USD
- Year-over-year change
- +36.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.87M) | +36.6% |
| FY2024 | 2024-12-31 | (53.41M) | -8.4% |
| FY2023 | 2023-12-31 | (49.28M) | -87.3% |
| FY2022 | 2022-12-31 | (26.31M) | -73.8% |
| FY2021 | 2021-12-31 | (15.14M) | — |
EBITDA vs competitors
How CDXS compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +62.9% is the highest of 10, against a peer median of +7.0%.
- EBITDA amounts to 28.2% of revenue for CDXS, versus a peer median of 696.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$22.06M USD | +62.9% | — | 28.2% | |
| LTM Mar 2026 | -$33.38M USD | +31.6% | — | 1053.3% | |
| LTM Mar 2026 | -$33.82M USD | +24.4% | — | 117.0% | |
| FY2025 | -€43.65M EUR | +7.0% | — | 1566.1% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$45.4M USD | +19.5% | — | 2329.5% |
| LTM Mar 2026 | -$62.94M USD | -39.6% | — | — | |
| LTM Mar 2026 | -$75.72M USD | +45.7% | — | 135.5% | |
| LTM Mar 2026 | -$100.38M USD | -3.7% | — | 287.9% | |
| LTM Mar 2026 | -$117.46M USD | -66.2% | — | 339.9% | |
| LTM Mar 2026 | -$262.46M USD | -2046.7% | — | 8872.8% | |
| Peer median (excluding CDXS) | — | +7.0% | — | 696.6% | |
Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 104.75M | 138.59M | 70.14M | 59.35M | 70.39M |
| Cost of Revenue | 22.21M | 38.03M | 12.81M | 16.29M | 9.34M |
| Gross Profit | 82.55M | 100.56M | 57.33M | 43.06M | 61.05M |
| Gross Margin | 78.8% | 72.6% | 81.7% | 72.6% | 86.7% |
| Research & Development | 55.92M | 80.1M | 58.89M | 46.26M | 52.31M |
| Selling, General & Admin | 49.32M | 52.17M | 53.25M | 55.15M | 47.07M |
| Operating Expenses | 105.24M | 135.44M | 125.4M | 101.58M | 99.38M |
| Depreciation & Amortization | 5.95M | 5.4M | 5.52M | 4.95M | 5.25M |
| EBITDA | (15.14M) | (26.31M) | (49.28M) | (53.41M) | (33.87M) |
| EBITDA Margin | -14.5% | -19.0% | -70.3% | -90.0% | -48.1% |
| Operating Income | (22.7M) | (34.88M) | (68.07M) | (58.52M) | (38.33M) |
| Operating Margin | -21.7% | -25.2% | -97.0% | -98.6% | -54.5% |
| Interest Income | 459K | 1.44M | 4.17M | 3.67M | 2.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 4.81M |
| Other Income / Expenses | 1.61M | 1.57M | (8.1M) | (6.72M) | (5.6M) |
| Income Before Tax | (21.09M) | (33.32M) | (76.17M) | (65.24M) | (43.93M) |
| Pre-Tax Margin | -20.1% | -24.0% | -108.6% | -109.9% | -62.4% |
| Income Tax Expense | 189K | 276K | 69K | 34K | 47K |
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Net Margin | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% |
| EPS (Basic) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| EPS (Diluted) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| Weighted Avg Shares | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
| Weighted Avg Shares (Diluted) | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.